Search Results

NeuBase Therapeutics, Inc. reported that it received a notice on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250 as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 in a timely manner.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023.

NeuBase Therapeutics, Inc., a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, announced that its Board of Directors has completed a review of the Company’s business, including the status of its programs, resources, and capabilities.

NeuBase Therapeutics, Inc. announced that the Company’s management will participate in the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on June 7-9, 2023.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments.

NeuBase Therapeutics, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, to be effective as of 5:00 p.m. Eastern Time today, June 14, 2023.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today announced a broad set of preclinical data, including non-human primate (“NHP”) repeat dosing data, for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system.

NeuBase Therapeutics, Inc. announced the formation of a gene editing advisory board comprised of distinguished leaders of the scientific community who will support the development of the differentiated gene editing capabilities of the Company’s PATrOL™ platform.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting.

NeuBase Therapeutics, Inc. today announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system.